# A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer

Source: https://onco.cc/trials/nct06196736/  
OnCo record `nct06196736` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of 9MW2821 in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.

## Summary

A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer is a phase 3 interventional study registered as NCT06196736 by Mabwell (Shanghai) Bioscience Co., Ltd., with 432 participants planned, started 2023-12-29 and due to reach its primary completion in 2026-09. Interventions recorded: 9MW2821 and Chemotherapy.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06196736
- Phase: 3
- Setting: An Open-label, Randomized Phase 3 Study to Evaluate 9MW2821 vs Investigator's Choice of Chemotherapy in Subjects With Locally Advanced or Metastatic Urothelial Cancer Who Have Previously Received PD-(L)1 Inhibitor and Platinum-containing Chemotherapy
- Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- Enrolled: 432

## Sources

- ClinicalTrials.gov NCT06196736: https://clinicaltrials.gov/study/NCT06196736

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)

---
JSON: https://onco.cc/api/v1/entities/nct06196736.json